T-SIGn Platform
®
Akamis Bio’s T-SIGn® therapeutics are based on a replication competent, chimeric group B adenovirus backbone which has been adapted via directed evolution to home specifically to both primary and metastatic epithelial-derived solid tumor tissue following intravenous delivery.
Once at the tumor site, T-SIGn® therapeutics can drive the intratumoral expression of multiple transgene payloads, turning solid tumor cells into “drug factories” while leaving healthy tissue unaltered and intact.
The intratumoral expression of immunologically active biomolecules and therapeutic proteins results in the remodeling of the solid tumor microenvironment and triggering of robust antitumor immune responses which aim to enable a patient’s own immune system to recognize, attack & clear their cancer.
T-SIGn® therapeutics have the potential to be used in the monotherapy setting, as well as in combination with other immuno-oncology agents to target the key mechanisms that tumors use to evade the immune system (e.g., downregulation of tumor antigen presentation, local immunosuppression in the tumor microenvironment, and stromal barriers to immune cell infiltration).
1
Transgene Payloads
MULTI-THERAPEUTIC FLEXIBILITY
Cytokines Bispecifics
Chemokines Synthetic Payloads
Antibodies etc.
PROPRIETARY VECTOR SYSTEM
Allows up to five transgenes providing tumor-specific expression of novel payload combinations in one treatment modality
2
T-SIGn Therapeutic
®
3
Intravenous Delivery
Targets primary and metastatic tumors
as a monotherapy or in combination
(e.g with CAR T-cell therapy)
Standard of care or other
Immuno-Oncology Therapies
(e.g. CAR T-cell therapy)
Primary
Tumors
Metastic
Tumors
Tumor-specific Replication
and Payload Production
-
Harness endogenous immunity
-
Express T cell chemo-attractants
-
Express cytokines, antibodies or other immunomodulators
-
Cell surface or spray-painted antigens
-
Activate and direct exogenous therapies
-
CAR-T/NK
-
TUMOR SHRINKAGE
4
Tumor Cells
LOCAL
TRANSGENE
EXPRESSION
ACTIVATION OF
ANTI-TUMOR IMMUNITY
APC
T cell
The possibilities are endless.
The combination of Akamis Bio’s T-SIGn® therapeutic design capabilities with our deep expertise in immunology and cancer biology opens the door to a multitude of novel therapeutic immuno-oncology approaches for treating solid tumors.
In addition to T-SIGn® therapeutic-mediated delivery of conventional immunologically active biomolecules and therapeutic proteins (e.g., antibodies, antibody fragments, bispecifics, cytokines, & chemokines), Akamis Bio is also exploring T-SIGn® therapeutics with novel synthetic payload designs with the potential to rationally target specific epithelial derived solid tumor types.
